Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Noida: A fire broke out in the basement of a district hospital in Sector 39 in Noida on Wednesday morning, prompting doctors to relocate 25 patients from the first floor to the emergency ward and ICU.
The incident occurred at 3:55 AM, prompting an immediate response from the fire department with the deployment of eight fire tenders.
Chief Fire Officer Pradeep K Chaubey said that as soon as the information was received, eight fire tenders reached the spot and doused the fire.
According to an ANI report, “At 3:55 AM, the fire service unit received information via the control room that a fire had broken out in the basement of the government hospital in Sector 39. Promptly, we dispatched 8 vehicles to the hospital. The smoke, which had started due to the fire, began to fill the first floor. During this time, the doctors did an excellent job by immediately moving 25 patients from the first floor to the emergency ward and ICU,” Chaubey said.
No one was injured in the incident, and the fire, which started in a UPS battery located in the building’s basement, was successfully extinguished.
Also Read:Fire breaks out at Bengaluru’s Raksha Hospital, 16 patients shifted
“Our team arrived and extinguished the fire using fire extinguishers,” he added.
The fire, attributed to a recently replaced Uninterruptible Power Supply (UPS) battery, was contained and extinguished using fire extinguishers.
Chaubey said,”The cause of the fire was determined to be an Uninterruptible Power Supply (UPS) battery, which had been replaced just 25 days ago”,news agency ANI reported.
“Due to the swift action by the doctors, no one was injured, and everyone is safe,” he added.
Earlier, a massive fire broke out in a factory at Sahibabad Site 4 Industry area in Uttar Pradesh’s Ghaziabad in the early hours of May 6.
Upon receiving the information, 18 fire tenders rushed to the spot and doused the fire.
Powered by WPeMatico
New Delhi: The National Medical Commission (NMC) has decided to adopt a uniform fee structure for medical colleges and individuals filing 1st and 2nd appeals before the Commission. Further, the NMC has warned the concerned that in case of deficiencies, the appeals are liable to be rejected on technical grounds.
In its 13th meeting, the Apex Medical Regulator in the country decided on a uniform fee of Rs 50,000 in cases of appeals filed by colleges or institutes related to the academic year 2024-2025 onwards. The Commission decided that Rs 5,000 shall be charged in all the cases of appeals filed by individuals.
NMC announced its decision through the recent notice dated 21.05.2024 stating that “The Commission in its 13th Meeting has decided to adopt a uniform fee of Rs. 50,000/- in cases of appeals filed by colleges/ Institutions related to academic year 2024-25 onwards and Rs. 5,000/- in all cases of appeals filed by Individuals. This will revise the different amounts of appeal fee earlier applicable for appeals in matter of different type of applications.”
Further, NMC mentioned in the notice that “it has also been decided that all appeals against the orders of the Boards under the Commission shall henceforth be addressed to Secretary, NMC only.”
“Therefore, all concerned colleges/ appellants are hereby informed that all appeals against the orders of Boards under the Commission as provided under different sections of NMC Act, 2019 may be preferred via ONLINE MODE ONLY through email at ‘nmc_appeal@nmc.org.in’ and addressed to “Secretary, NMC” within the stipulated time period as per the NMC Act. Appeals received through any other mode/channel or email address will be liable not to be considered,” the notice further stated.
Medical Dialogues had earlier reported that last year NMC specified the process of filing 1st and 2nd appeals after noting that several medical colleges or appellants were still not following the prescribed procedure for filing appeals.
Back then, NMC had provided a checklist for all the requisite documents that the medical colleges required to submit along with the appeal and the processes that the appellant or college needed to ensure.
Previously, on 28.12.2022 also, the Commission had prescribed the procedure for filing 1st/2nd appeals before the Commission under the NMC Act, 2019.
In the recent notice dated 21.05.2024, NMC referred to its notices issued earlier while addressing the issue of filing 1st/2nd appeals under under relevant sections [u/s 22(3), 28(5), 30(4), 35(5)] of NMC Act, 2019.
“This Commission has earlier issued public notices dated 28.12.2022 and 28.08.2023 (copy enclosed) prescribing therein steps/ procedure for filing 1 st / 2 nd appeals before the National Medical Commission (NMC) under the NMC Act, 2019,” NMC mentioned in the notice.
The Apex Medical Regulator highlighted that despite issuing such guidelines, many medical colleges were found not complying with due procedure for filing appeals. Pointing out the various counts in which the appeals were found to be deficient, the NMC notice stated, “Despite these guidelines, it has been observed that many colleges/ appellants are still not following the due procedure for filing appeals under the aforesaid sections of NMC Act as per said public notices. A number of appeals received in this Commission are deficient on various counts; invoking wrong section of the NMC Act; non-submission of all documents as per checklist prescribed in the public notice, appeal submission to non-concerned authority etc. which make them liable to be rejected on technical grounds.”
“In this regard, it is reiterated that all concerned may go through before submitting any appeal to this commission against decision of any board,” it further added.
To view the NMC notice, click on the link below:
https://medicaldialogues.in/pdf_upload/nmc-appeal-238902.pdf
Powered by WPeMatico
USA: Continuous glucose monitoring (CGM) emerges as a beacon of hope in the battle against type 2 diabetes mellitus (T2DM), as per a recent systematic review and meta-analysis of randomized controlled trials. The study, conducted by a team of researchers, delves into CGM’s effectiveness in enhancing metrics of glycemic control among individuals grappling with T2DM.
The study published in The Journal of Clinical Endocrinology & Metabolism revealed that continuous glucose monitors (CGMs) or flash glucose monitors (FGM) use led to a statistically significant decrease in A1C for adults with type 2 diabetes.
“Our analyses showed that initiation of CGM led to a modest but significant decline in HbA1c of 0.32% among patients with T2DM,” the researchers reported. They note that declines in HbA1c were similar for both rt-CGM and FGM, however, there was a trend for improvements in other metrics of glucose control that favored rt-CGM over self-monitoring blood glucose (SMBG).
Stacey Uhl, ECRI, Plymouth Meeting, PA, USA, and colleagues aimed to provide a systematic review and meta-analysis synthesizing the findings of randomized controlled trials (RCTs) of CGMs in managing adults with type 2 diabetes on glucose control and clinical outcomes.
For this purpose, the researcher searched the online databases for RCTs that assessed the effectiveness of FGM or real-time CGM (rt-CGM) in adults with T2DM that reported on at least 1 of the following outcomes: time in hyperglycemia, time in range, hemoglobin A1c (HbA1c), or time in hypoglycemia. The certainty of evidence for primary outcomes was assessed using the GRADE approach.
The researchers reported the following findings:
Flash CGM and rt-CGM led to modest but statistically significant reductions in HbA1c among individuals with T2DM, with little heterogeneity in the results. However, the duration of the included RCTs was relatively short, and few studies reported on important clinical outcomes, such as emergency department use, adverse events, or hospitalization.
“There is a need for longer-term studies to determine if the short-term improvements in glucose control lead to improvements in clinically important outcomes,” the researchers wrote.
Reference:
Uhl, S., Choure, A., Rouse, B., Loblack, A., & Reaven, P. (2024). Effectiveness of Continuous Glucose Monitoring on Metrics of Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. The Journal of Clinical Endocrinology & Metabolism, 109(4), 1119-1131. https://doi.org/10.1210/clinem/dgad652
Powered by WPeMatico
Researchers have found that regular use of melatonin supplements is not associated with an increased risk of developing type 2 diabetes or cardiovascular disease (CVD) in adults. This conclusion comes from a comprehensive study involving three large U.S. cohorts, aimed at assessing the long-term cardiometabolic effects of melatonin supplement use. This was published in The Lancet. Diabetes & Endocrinology by Yanping Li. and colleagues.
The use of melatonin supplements has risen significantly in recent years among both children and adults in the USA. However, their long-term effects on cardiometabolic health remain uncertain. To address this gap, researchers analyzed data from the Nurses’ Health Study (NHS), Health Professionals Follow-up Study (HPFS), and the Nurses’ Health Study II (NHS II) to determine the association between melatonin supplement use and the incidence of type 2 diabetes and cardiovascular disease.
This study included 67,202 women from the NHS, 26,629 men from the HPFS, and 65,241 women from the NHS II. Participants were aged 25-55 years (women) and 45-75 years (men) at baseline, with no prior diagnosis of cancer, cardiovascular disease, or type 2 diabetes. The main outcomes were the incidence of cardiovascular disease and type 2 diabetes, with follow-up periods extending up to 23 years.
Melatonin supplement use was assessed via self-reported questionnaires. The researchers also conducted secondary analyses to evaluate the effects of melatonin use among participants with long-term rotating night shift work, a known risk factor for adverse cardiometabolic outcomes.
Over the follow-up period, the prevalence of melatonin supplement use doubled, rising from less than 2% in 1998-2007 to over 4% by 2014-2015, with 4.0% usage in men and 5.3% in women.
The study documented 16,917 incident cardiovascular disease events and 12,730 incident cases of type 2 diabetes across 2,609,068 and 2,701,830 person-years of follow-up, respectively.
The pooled multivariable-adjusted hazard ratio for cardiovascular disease among melatonin users compared to non-users was 0.94 (95% CI 0.83–1.06, p=0.32), indicating no significant association.
The pooled multivariable-adjusted hazard ratio for type 2 diabetes was 0.98 (95% CI 0.86–1.12, p=0.80), also showing no significant link between melatonin use and diabetes risk.
In secondary analyses, melatonin supplement use appeared to attenuate the increased risk of cardiovascular disease associated with long-term rotating night shift work (>5 years) among female nurses (p_interaction=0.013).
The results suggest that regular melatonin supplement use is not associated with an increased risk of type 2 diabetes or cardiovascular disease. This finding provides reassurance to the growing number of individuals using melatonin supplements for sleep-related issues. Notably, the study also highlighted a potential protective effect of melatonin against the cardiometabolic risks associated with long-term shift work, particularly in women.
With up to 23 years of follow-up data from three large cohorts, this study provides strong evidence that melatonin supplement use does not increase the risk of developing type 2 diabetes or cardiovascular disease in middle-aged and older adults. Further research is warranted to explore the potential benefits of melatonin in mitigating risks associated with shift work.
Reference:
Li, Y., Huang, T., Redline, S., Willett, W. C., Manson, J. E., Schernhammer, E. S., & Hu, F. B. (2024). Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies. The Lancet. Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(24)00096-2
Powered by WPeMatico
Researchers have found that while β-lactam (BL) allergies are not associated with increased long-term mortality, they are linked to higher rates of antibiotic-resistant infections. This finding is based on a longitudinal retrospective cohort study conducted at a regional health care system in western Pennsylvania, highlighting the need for accurate allergy documentation and cautious antibiotic stewardship. This study was published in JAMA Network Open by Matthew P. and colleagues.
BL allergies are the most common drug allergies worldwide, often reported erroneously. These allergies are known risk factors for adverse drug events and antibiotic-resistant infections during inpatient care, but their long-term outcomes have been less understood. This study aimed to evaluate the long-term clinical outcomes of patients with documented BL allergies.
The study analyzed electronic health records of patients with an initial diagnosis of sepsis, pneumonia, or urinary tract infection between 2007 and 2008. These patients were followed up until death or the end of 2018. Data analysis was performed from January 2022 to January 2024. The presence of any BL class antibiotic allergy in the patient’s electronic health record was evaluated at their earliest recorded health care encounter.
The primary outcome was all-cause mortality, obtained from the Social Security Death Index. Secondary outcomes included infections with methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, or vancomycin-resistant Enterococcus (VRE), as well as the severity and occurrence of acute kidney injury (AKI). Odds of these outcomes were evaluated using generalized estimating equations.
The study included 20,092 patients (mean age 62.9 years; 60.9% female). Of these, 4211 (21.0%) had a documented BL allergy, and 15,881 (79.0%) did not. The cohort comprised 17.5% Black, 76.4% White, and 6.0% other races.
BL allergies were not significantly associated with the odds of mortality (OR, 1.02; 95% CI, 0.96-1.09).
BL allergies were associated with increased odds of MRSA infection (OR, 1.44; 95% CI, 1.36-1.53), VRE infection (OR, 1.18; 95% CI, 1.05-1.32), and the pooled rate of the three antibiotic-resistant infections (OR, 1.33; 95% CI, 1.30-1.36).
There was no significant association with C. difficile infection (OR, 1.04; 95% CI, 0.94-1.16).
There was also no significant association with stage 2 and 3 AKI (OR, 1.02; 95% CI, 0.96-1.10) or stage 3 AKI (OR, 1.06; 95% CI, 0.98-1.14).
The findings indicate that while BL allergies do not impact long-term mortality, they do significantly increase the risk of antibiotic-resistant infections such as MRSA and VRE. This underscores the importance of precise allergy documentation and the reduction of unnecessary BL antibiotic avoidance, which may help in managing and preventing resistant infections.
Documented BL allergies were not linked to increased long-term mortality but were associated with higher rates of antibiotic-resistant infections. Health systems should prioritize accurate allergy documentation and minimize unnecessary avoidance of BL antibiotics to mitigate the risks of antibiotic resistance.
Reference:
Gray, M. P., Kellum, J. A., Kirisci, L., Boyce, R. D., & Kane-Gill, S. L. (2024). Long-term outcomes associated with β-lactam allergies. JAMA Network Open, 7(5), e2412313. https://doi.org/10.1001/jamanetworkopen.2024.12313
Powered by WPeMatico